A variety of nitric oxide-releasing vascular grafts and prostheses are provided. Methods of making the nitric oxide-releasing vascular grafts and prostheses are also provided. Methods of administering the nitric oxide-releasing vascular grafts and prostheses to a subject in need thereof are also provided. The nitric oxide-releasing vascular grafts and prostheses have a base layer made of a graft material and a nitric oxide-releasing layer made from a polymer matrix including a plurality of polysiloxanes and a plurality of nitric oxide-donating crosslinking moieties covalently crosslinking polysiloxanes in the plurality of polysiloxanes. In some aspects, the vascular grafts and prostheses can provide for reduced infection rates and increased patency by providing for prolonged local delivery of nitric oxide when implanted in a vessel of a subject in need thereof.

A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures.

A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures.

The invention relates to an implantable medical device having a body comprising a composite material. The body has a variable cross section along a length, a first portion which forms a part of a surface of said body, and a packing portion. An insert is provided in the packing portion for providing an increased thickness to at least a part of the body.

A composition for the treatment of wounds includes demineralized bone fibers (DBF) derived from allogeneic or xenogenic cortical bone and/or polymeric fibers made from resorbable and/or non-resorbable polymer, and the composition may also include an oxygen-generating material and/or an oxygen carrier.

A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

A preparation method comprises following steps: S1: dissolving a coupling agent in an ethanol solution, adding an ultrafine radiopaque agent powder in the ethanol solution, and obtaining a modified ultrafine radiopaque agent powder by agitation, washing and drying, the ultrafine radiopaque agent powder having a particle size of 0.35-0.8 μm; S2: obtaining the radiopaque material by mixing a medical polymeric material with the modified ultrafine radiopaque agent powder. A prepared radiopaque material exhibits not only radiopaque functions but also good mechanical properties of improved elastic modulus, fracture strength and bending modulus, thereby expanding application of medical polymer hollow fibers in high-end medical products for minimally invasive intervention. Particularly, delivery devices applied with prepared radiopaque material have improved pushing and torque performance and are suitable for ultra-smooth guidewires, heart valve prostheses, guiding catheters, and degradable balloons.

A preparation method comprises following steps: S1: dissolving a coupling agent in an ethanol solution, adding an ultrafine radiopaque agent powder in the ethanol solution, and obtaining a modified ultrafine radiopaque agent powder by agitation, washing and drying, the ultrafine radiopaque agent powder having a particle size of 0.35-0.8 μm; S2: obtaining the radiopaque material by mixing a medical polymeric material with the modified ultrafine radiopaque agent powder. A prepared radiopaque material exhibits not only radiopaque functions but also good mechanical properties of improved elastic modulus, fracture strength and bending modulus, thereby expanding application of medical polymer hollow fibers in high-end medical products for minimally invasive intervention. Particularly, delivery devices applied with prepared radiopaque material have improved pushing and torque performance and are suitable for ultra-smooth guidewires, heart valve prostheses, guiding catheters, and degradable balloons.

A three-dimensional, biocompatible scaffold precursor composition for room-temperature printing a bio-compatible polymer/hydroxyapatite composite scaffold includes a room-temperature slurry, comprising a mixture of a sold phase that includes a mixture of tetracalcium phosphate (TTCP; Ca.sub.4(PO.sub.4).sub.2O) and dicalcium phosphate anhydrous (DCPA; CaHPO.sub.4), and a liquid phase that includes a polymer in a solvent. The solvent may be Ethanol (EtOH) or Tetrahydrofuran (THF), and the polymer may be polyvinyl butyral (PVB), polycaprolactone (PCL), or poly lactic-co-glycolic acid (PLGA). The slurry is printed at room temperature in aqueous phosphate (NaH.sub.2PO.sub.4) bath, which works as hardening accelerator, forming the polymer/hydroxyapatite composite scaffold